中文摘要：

造血干细胞移植（hematopoietic stem cell transplantation，HSCT）是一种有效的，有时是唯一的根治性治疗某些血液疾病的治疗方法。单倍型HSCT已在国际上实行约20余年，在过去的10年中，中国原创的非体外去T细胞单倍型移植体系为单倍型HSCT的改进做出突出贡献，使得HSCT实现人人都有供者。本文旨在描述当前HSCT的状况，并展望中国HSCT体系的未来前景。

英文摘要：

Hematopoietic stem cell transplantation （HSCT） is the only effective curative therapy for patients with certain hematological diseases. Haploidentical HSCT has been practiced worldwide for approximately twenty years. Significant improvements on this therapy were made in China within the past decade, with the novel non-in-vitro, T-cell-depleted haploidentical HSCT system. This review describes the current situation and provides a prospective overview of these novel HSCT systems in China.